Nottingham, UK – 27th April 2004 – Scancell Ltd, the Nottingham, UK based cancer therapeutics company, announced at its annual general meeting (AGM) today the successful completion of a further round of private equity funding totalling ~£1.3 million. Bioscience VCT, and Oxford Technology 3 VCT, an existing investor, acted as co-lead investors for the round. Other new investors in this round included Oxford Capital Partners and Cherwell Capital. Several of Scancell’s existing investors also made additional investments in the company.
The new funding will allow Scancell to accelerate the development of its leading products and to move to dedicated laboratories at the new BioCity Healthcare and Bioscience Innovation Centre in Nottingham, UK.
Commenting on the funding Dr Mike Capaldi, Scancell’s new CEO said:
“Scancell is very pleased to have succeeded in securing this investment in the current difficult market conditions. The company has already demonstrated its ability to develop new products and close commercial deals. The new investment will allow the company to bring its products closer to the clinic and to further develop its ImmunoBody® programme. We are also very excited about the move to BioCity, which will significantly help our growth plans.”
Dr Paul Nicholson, the Chairman of BioScience VCT, said:
“We are pleased to have made an investment in Scancell. The company has built a strong team to lead the development of its antibodies and its platform technologies and we look forward to supporting the company’s progress.”
Lucius Cary, Director of Oxford Technology 3 VCT, and the Managing Director of Seed Capital Ltd, the Investment Adviser to the Oxford Technology 3 VCT added:
“We are very pleased to have invested further in Scancell and continue to support the company and the research of its founder, Professor Lindy Durrant. This is a company that has developed a diverse pipeline of anti-cancer targets and platform technologies and assembled an outstanding team to deliver these to the clinic.”
After buying 77.56mln new shares at a price of 5p per share, which was a slight discount to the 5.35p closing price the previous day, the Vulpes Life Sciences Fund will have a 16.67% stake in the company.
Fri, 21 Jun 2019 08:21:00
Scancell Holdings PLC (LON:SCLP) CEO Cliff Holloway caught up with Proactive London's Andrew Scott following the announcement they'd raised £3.88mln via a placing with a single new investor to help fund the progression of its lead cancer asset into clinical trials.
The Vulpes Life Sciences Fund will now have a 16.67% stake in the company when the shares are issued next Monday.
Thu, 13 Jun 2019 09:53:00
“At Vulpes we are always searching for overlooked companies that have the ability to make significant advances in medical science, with a view to supporting their development over the long term. We believe Scancell fulfil these criteria perfectly.”
Thu, 13 Jun 2019 06:31:00